In 2002, the World Health Organization (WHO) recommended the use of artemisinin-based combination therapy (ACT) for the treatment of all cases of uncomplicated malaria. The pyronaridine-artesunate combination (Pyramax®) is one of the latest oral ACTs recommended for the treatment of uncomplicated *P. falciparum* and *P. vivax* malaria \[[@CR1]\]. The combination pyronaridine-artesunate has recently completed phase III trials in humans. The safety and efficacy of this compound were shown in four randomized clinical trials in adults and children in Africa and Asia \[[@CR2]--[@CR5]\]. Pyronaridine-artesunate showed better efficacy compared with mefloquine-artesunate for the treatment of uncomplicated falciparum malaria in Cambodia and a non-inferior efficacy compared with artemether-lumefantrine in Africa and Southeast Asia. The emergence of *P. falciparum* resistance to artemisinin and artemisinin derivatives has recently developed in Southeast Asia, manifesting as delayed parasite clearance following treatment with artesunate monotherapy or ACT \[[@CR6], [@CR7]\]. Resistance has still developed with the most recent ACT in the form of dihydroartemisinin-piperaquine, which demonstrated less than 70 % efficacy \[[@CR8], [@CR9]\]. In areas where the resistance of artemisinin is emerging, partner drugs are under increasing pressure for the selection of resistance, and new therapeutics are limited. Thus, it is important to use an ACT in which its partner drug shows a different mode of action or mechanism of resistance. The in vitro responses to pyronaridine and piperaquine were differently distributed in a triple normal distribution model for pyronaridine and a quadruple normal distribution model for piperaquine \[[@CR10]\]. Significant positive in vitro cross-susceptibility was observed between pyronaridine and piperaquine (coefficient of determination of 0.20--0.23) \[[@CR11], [@CR12]\]. In vitro and ex vivo responses to piperaquine were not associated with the K76T mutation in the *P. falciparum* chloroquine resistance transporter gene (*pfcrt*) \[[@CR13], [@CR14]\]. Few data are available on the association between pyronaridine susceptibility and polymorphisms in the genes involved in antimalarial drug resistance. A study using 23 *P. falciparum* strains showed that there was no significant association between in vitro responses to pyronaridine and *pfcrt* polymorphism \[[@CR15]\]. The objective of the present study was to investigate the association between *ex vivo* responses to pyronaridine and the K76T mutation in the *pfcrt* gene in 296 *P. falciparum* African isolates.

In total, 296 *P. falciparum* isolates were collected between April 2008 and August 2012 from patients hospitalized in France with imported malaria from African malaria-endemic countries (Angola, Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Comoros, Congo, Ivory Coast, Gabon, Gambia, Ghana, Guinea, Madagascar, Mali, Mauritania, Mozambique, Niger, Senegal, Togo, and Zambia). Informed consent was not required for this study because the sampling and testing procedures were conducted according to the French national recommendations for the care and surveillance of malaria. The *ex vivo* responses to pyronaridine (Shin Poong Pharm Co., Seoul, Korea) and chloroquine (St. Louis, MO, USA) (control for *pfcrt* polymorphism) were assessed as previously described using a standard 42-h 3H-hypoxanthine uptake inhibition method \[[@CR10]\]. Batches of plates were tested and validated using the chloroquine-susceptible 3D7 strain (West Africa) and the chloroquine-resistant W2 strain (Indochina) (MR4, Virginia, USA) in three to six independent experiments. Nucleic acid extraction and *pfcrt* single-nucleotide polymorphism identification were previously described \[[@CR14]\].

The pyronaridine IC~50~ values (inhibitory concentration 50 %) ranged from 0.55 to 80.0 nM (Fig. [1](#Fig1){ref-type="fig"}). The geometric mean was 20.8 ± 14.6 nM (standard deviation). *Ex vivo* responses to pyronaridine were significantly associated with the K76T mutation (*p*-value = 0.020), and similar results were obtained for chloroquine IC~50~ (*p*-value \< 0.001). Sixteen isolates (5.4 %) had an IC~50~ greater than 60 nM and were considered to display reduced susceptibility to pyronaridine in vitro \[[@CR10]\]. The reduced susceptibility to pyronaridine, defined as IC~50~ \> 60 nM, was significantly associated with the K76T mutation (*p*-value = 0.004). The odds ratio for reduced susceptibility to pyronaridine associated with the K76T mutation was 4.47 (95 % CI \[1.39--18.84\]). The in vitro resistance to chloroquine, defined as IC~50~ \> 100 nM, was also significantly associated with the K76T mutation (*p*-value \< 0.001). The odds ratio for reduced susceptibility to chloroquine associated with the K76T mutation was 96.4 (95 % CI \[41.8--244.8\]). Using Bayesian mixture modelling, the 296 pyronaridine IC~50~values were classified into three components: component A (IC~50~ median 15.9 nM), component B (IC~50~ median 34.2 nM) and component C (IC~50~ median 63.3 nM) (Table [1](#Tab1){ref-type="table"}). The pyronaridine medians were significantly different in the three components (Kruskal-Wallis test, *p*-value \< 0.001). The proportion of isolates in each group was 59.8 % for component A, 30.1 % for component B and 10.1 % for component C. The K76T mutation represented 46.3 % of the isolates in component A, 47.2 % of the isolates in component B and 73.3 % of the isolates in component C (Kruskal-Wallis test, *p*-value = 0.021).Fig. 1Pyronaridine median and 25 and 75 percentiles of the 50 % inhibitory concentration (IC50 in nM) of 296 African *Plasmodium falciparum* isolatesTable 1Distribution of the IC~50~ of pyronaridine and chloroquine and the K76T mutation according to the three components defined by the Bayesian mixture modeling approachComponent AComponent BComponent C*P*-valueNo of isolates1778930Pyronaridine median IC~50~15.9 nM34.2 nM63.3 nM\<0.001Pyronaridine 25 % percentile11.2 nM30.4 nM51.2 nMPyronaridine 75 % percentile18.5 nM37.1 nM69.7 nMChloroquine median IC~50~57.0 nM90.6 nM240.5 nM0.003Chloroquine 25 % percentile18.3 nM19.7 nM71.2 nMChloroquine 75 % percentile207 nM273 nM301 nMNo of K76T mutation (%)82 (46.3)42 (47.2)22 (73.3)0.021

The results of the present study showed that *ex vivo* reduced susceptibility to pyronaridine, i.e., IC~50~ \> 60 nM, was associated with the K76T mutation in the *pfcrt* gene. These *ex vivo* results are in contrast with the in vitro results in 23 *P. falciparum* strains in which the in vitro to pyronaridine were not associated with *pfcrt* polymorphisms \[[@CR15]\]. However, none of the 23 strains showed reduced susceptibility to pyronaridine. In 59 field isolates from Kenya, pyronaridine was more active in vitro against parasites harbouring the wild-type sequence than against those harbouring the K76T mutation (IC~50~ of 6 versus 20 nM). However, this difference was not significant (*p*-value \> 0.05) \[[@CR16]\]. The odds ratio for the K76T mutation associated with reduced susceptibility to pyronaridine was 4.47, whereas the odds ratio for in vitro resistance to chloroquine was 96.4. The resistance to pyronaridine is certainly multigenic, and additional polymorphisms in other genes could also be involved in this resistance.

In contrast with piperaquine, in which its in vitro responses are not associated with *pfcrt* polymorphism in isolates from Africa and Asia \[[@CR13], [@CR14], [@CR17], [@CR18]\] but rather associated with repeat polymorphisms in an ABC transporter gene, *pfmdr6* \[[@CR19]\], pyronaridine mechanisms of resistance are different than those involved in piperaquine. Pyronaridine-artesunate could be used in areas where resistance to other ACTs has already emerged.

Pyronaridine-artesunate successfully treats artemisinin-resistant *P. berghei* parasites, while artemether-lumefantrine, artesunate-amodiaquine, artesunate-mefloquine and dihydroartemisinin-piperaquine are not effective \[[@CR20]\]. Pyronaridine-artesunate showed better efficacy than mefloquine-artesunate for the treatment of uncomplicated falciparum malaria in Cambodia and a non-inferior efficacy compared with that of artemether-lumefantrine in Africa and Southeast Asia \[[@CR2]--[@CR4]\]. Pyronaridine-artesunate showed greater than 95 % efficacy when used as an initial falciparum malaria treatment versus the re-treatment of subsequent episodes in a multi-site trial in Mali, Burkina Faso and Guinea \[[@CR21]\]. In addition, pyronaridine-artesunate is also affective in the treatment of acute uncomplicated *P. vivax* malaria \[[@CR5]\]. Pyronaridine-artesunate is an alternative artemisinin-based combination treatment for malaria in sub-Saharan Africa.
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